Currently, PI3Kα-specific inhibitors are administered to PIK3CA-mutated tumors in combination with hormonotherapy; the clinical use of PI3Kα inhibitors could be extended to cancer with global PI3K/AKT activation (e.g., pancreatic cancer due to KRAS mutation) but not in single therapy and possibly with PI3Kγ inhibitors. This evidence concerns the gene PIK3CB and pancreatic neoplasm.